Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 03, 2022

SELL
$53.63 - $62.52 $632,780 - $737,673
-11,799 Closed
0 $0
Q3 2021

Oct 15, 2021

SELL
$59.17 - $69.31 $18,756 - $21,971
-317 Reduced 2.62%
11,799 $698,000
Q2 2021

Jul 20, 2021

BUY
$61.91 - $67.42 $557 - $606
9 Added 0.07%
12,116 $810,000
Q1 2021

Apr 14, 2021

BUY
$59.34 - $66.74 $474 - $533
8 Added 0.07%
12,107 $764,000
Q4 2020

Jan 25, 2021

BUY
$57.74 - $65.43 $85,974 - $97,425
1,489 Added 14.03%
12,099 $750,000
Q3 2020

Oct 09, 2020

BUY
$57.43 - $63.64 $459 - $509
8 Added 0.08%
10,610 $640,000
Q2 2020

Jul 14, 2020

BUY
$54.82 - $64.09 $438 - $512
8 Added 0.08%
10,602 $623,000
Q1 2020

Apr 15, 2020

BUY
$46.4 - $67.43 $8,862 - $12,879
191 Added 1.84%
10,594 $590,000
Q4 2019

Jan 14, 2020

BUY
$49.21 - $64.19 $41,730 - $54,433
848 Added 8.87%
10,403 $668,000
Q3 2019

Oct 25, 2019

BUY
$42.77 - $50.71 $9,409 - $11,156
220 Added 2.36%
9,555 $485,000
Q2 2019

Jul 26, 2019

SELL
$44.62 - $49.34 $14,189 - $15,690
-318 Reduced 3.29%
9,335 $423,000
Q1 2019

Apr 29, 2019

BUY
$45.12 - $53.8 $17,506 - $20,874
388 Added 4.19%
9,653 $461,000
Q4 2018

Jan 29, 2019

BUY
$48.76 - $63.23 $97 - $126
2 Added 0.02%
9,265 $482,000
Q3 2018

Oct 24, 2018

SELL
$55.19 - $62.25 $33,003 - $37,225
-598 Reduced 6.06%
9,263 $575,000
Q2 2018

Jul 30, 2018

BUY
$50.53 - $62.98 $101 - $125
2 Added 0.02%
9,861 $546,000
Q1 2018

Apr 23, 2018

BUY
$59.92 - $68.98 $10,066 - $11,588
168 Added 1.73%
9,859 $624,000
Q4 2017

Jan 24, 2018

BUY
$59.94 - $65.35 $2,697 - $2,940
45 Added 0.47%
9,691 $594,000
Q3 2017

Oct 19, 2017

BUY
$55.23 - $63.74 $532,748 - $614,836
9,646
9,646 $615,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Taylor, Cottrill, Erickson & Associates, Inc. Portfolio

Follow Taylor, Cottrill, Erickson & Associates, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Taylor, Cottrill, Erickson & Associates, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Taylor, Cottrill, Erickson & Associates, Inc. with notifications on news.